Introduction: Predictors of glucagon-like peptide-1 (GLP-1) responses following OGTT in treatment-naïve type 2 diabetes mellitus (T2DM) have not been fully elucidated. In this respect, we aim to investigate the various predictors of GLP-1 responses following OGTT in treatment-naïve T2DM.

Aim: To assess the clinical and biochemical predictors of GLP-1 responses following OGTT in treatment-naïve T2DM among three ethnic groups in Malaysia.

Methods : Thirty-one treatment-naive T2DM subjects underwent a 75-g OGTT. Total GLP-1 concentrations were measured at 0, 30 and 120 min. By using area under the curve (AUC) for GLP-1 (AUCGLP-1) as an index of GLP-1 secretory response, predictors of GLP-1 responses following OGTT were assessed using multiple linear regression analysis.

Results: Majority of the treatment-naïve T2DM patients were newly-diagnosed (n=28, 96.6%). The GLP-1 levels at 0, 30- and 120-min were 25.59 ± 10.87 pmol/L, 46.86 ± 18.36 pmol/L and 27.02 ± 13.37 pmol/L respectively. There was a positive correlation between increasing age and AUCGLP-1 (Β = 8.55, p<0.001). Male had higher GLP-1 response to OGTT than female (Β = -303.04, p<0.001). The Indian ethnicity exhibited higher GLP-1 secretion than the Malays (Β = 244.17, p<0.001). Fasting insulin was positively correlated with AUCGLP-1 (Β = 8.73, p=0.001). AUCGLP-1 was positively correlated with increased systolic blood pressure (Β = 3.65, p=0.03), total cholesterol (Β = 174.32, p=0.004) and LDL-cholesterol (Β = 202.35, p=0.002).

Conclusions: Older age, male and Indian ethnicity were independent predictors of GLP-1 responses following OGTT in treatment-naïve T2DM. The positive correlation between risk factors associated with insulin resistance and GLP-1 suggested that these risk factors are responsible for driving GLP-1 secretion.

Disclosure

S.Chong: None. N.Sukor: None. S.A.Robert: None. K.Ng: None. N.A.Kamaruddin: Advisory Panel; Zuellig Pharma Holdings Pte. Ltd., Other Relationship; American Association of Clinical Endocrinologists, Speaker's Bureau; AstraZeneca, Boehringer-Ingelheim, Eli Lilly and Company, Merck Sharp & Dohme Corp., Novo Nordisk.

Funding

National University of Malaysia (GUP-2017-066); Malaysian Endocrine & Metabolic Society (L12-MEMS6)

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.